<DOC>
	<DOCNO>NCT00452140</DOCNO>
	<brief_summary>The purpose study demonstrate clinical efficacy investigational trifunctional bispecific antibody ertumaxomab treatment patient HER-2/neu 1+ 2+ ( FISH- ) express advanced metastatic breast cancer ( stage III b/IV ) progress endocrine therapy . Ertumaxomab trifunctional bispecific antibody target Her-2/neu CD3 T cell . Trifunctional antibody represent new concept target anticancer therapy . This new antibody class capability redirect T cell accessory cell ( e.g . macrophage , dendritic cell [ DCs ] natural killer [ NK ] cell ) tumor site . According preclinical data , trifunctional antibody activate immune cell , trigger complex anti-tumor immune response .</brief_summary>
	<brief_title>Phase II Study With Trifunctional Antibody Ertumaxomab Treat Metastatic Breast Cancer Progressing After Endocrine Treatment</brief_title>
	<detailed_description>An open-label , non-randomized , uncontrolled , one-stage , phase II study evaluate efficacy safety investigational trifunctional bispecific antibody ertumaxomab ( anti-Her-2/neu x anti-CD3 ) treatment hormone therapy refractory advance metastatic breast cancer tumour ( stage IIIb IV ) know express HER-2/neu ( 1+ 2+/FISH negative ) .Ertumaxomab administered 7 day interval constant rate 3 hour intravenous ( i.v . ) infusion accord follow sequential dose schedule : 10 µg ( day 0 ) thereafter 100 µg flat dos every 7 day ( ± 1 day ) maximum 12 week disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed date informed consent form Women ≥ 18 year , negative pregnancy test screen life expectancy least 6 month Locally advance ( stage IIIb ) metastatic ( stage IV ) curable adenocarcinoma breast Measurable disease , define least one lesion measurable one dimension ( RECIST ) HER2/neu expression 1+ 2+ / FISH negative Estrogen Receptors ( ERs ) and/or Progesterone Receptors ( PRs ) positive Prior adequate endocrine therapy advance metastatic disease Disease progression endocrine therapy No prior treatment mouse rat antibody ECOG performance score ≤ 1 Adequate hematological , liver kidney function Women pregnant breastfeed Known HIV infection Presence autoimmune disease Concurrent nonmalignant comorbidities uncontrolled History symptom indicative brain CNS metastases Prior diagnosis malignancy cure surgery alone less 5 year study entry ( except situ carcinoma cervix adequately treat basal cell carcinoma skin ) Documented acute chronic infection require antibiotic treatment Any concurrent chemo , hormonal , immuno corticoid therapy Any prior chemotherapy advance metastatic disease Any concurrent investigational treatment advance metastatic disease History relevant cardiovascular disease follow : Left ventricular ejection fraction ( LVEF ) institution 's low limit normal , base echocardiography ( ECG ) rest Uncontrolled symptomatic congestive heart failure ( New York Heart Association ( NYHA ) &gt; 2 Uncontrolled symptomatic arrhythmia and/or angina pectoris Myocardial infarction last 2 year</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>investigational drug</keyword>
	<keyword>drug therapy</keyword>
	<keyword>Antineoplastic Protocols</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Stage III IV breast cancer</keyword>
	<keyword>Hormonal therapy refractory</keyword>
	<keyword>Failure hormonal therapy</keyword>
	<keyword>Her-2/neu express breast cancer</keyword>
	<keyword>Her-2/neu</keyword>
</DOC>